- $37.66m
- -$16.42m
- $20.60m
Brief: SCYNEXIS Reports Closing Of Exclusive License Agreement With GSK For Brexafemme
Scynexis Inc rises on closing deal with GSK for antifungal pill
Brief: Scynexis Inc Upon Receipt Of Upfront Payment From GSK, Will Have A Projected Cash Runway Of More Than Two Years
Scynexis Inc Reports Results For The Quarter Ended In March: Earnings Summary
Scynexis Inc Expected To Post A Loss Of 28 Cents A Share: Earnings Preview
Scynexis Inc Reports Results For The Quarter Ended In December: Earnings Summary
Scynexis Inc climbs after Q4 loss narrows, beats estimates
Brief: SCYNEXIS Reports Q4 Net Loss Of $0.30 Per Share
U.S. RESEARCH ROUNDUP- Cintas, Stryker, Zimmer Biomet Holdings
U.S. STOCKS ON THE MOVE-Piedmont Lithium, Walmart, Kilroy Realty
U.S. STOCKS ON THE MOVE-Walmart, JD.Com, Crinetics
GSK sees $500 mln peak sales for yeast infection pill licensed from Scynexis (updated)
GSK sees $500 mln peak sales for yeast infection pill licensed from Scynexis
U.S. STOCKS ON THE MOVE-Neogen Corp, Freight Technologies, Philip Morris
Biotech firm SCYNEXIS soars on GSK licensing agreement
U.S. STOCKS ON THE MOVE-Safe & Green Holdings, Medical Properties Trust, Gold miners
Brief: Scynexis Entered Into License Agreement With GSK
Scynexis Inc Expected To Post A Loss Of 44 Cents A Share: Earnings Preview
Brief: Scynexis Announces FDA Approval Of Second Indication For Brexafemme® (Ibrexafungerp Tablets) For Reduction In Incidence Of Recurrent Vulvovaginal Candidiasis